Topical tacrolimus in the management of lichen sclerosus.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 16827768.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The effective management of vulval lichen sclerosus (LS) currently depends upon the use of topical steroids and emollients. There are concerns with regard to the long-term toxicity of potent steroids and therefore is a need to consider effective alternatives. Immunomodulatory macrolactams offer an alternative to steroids in the management of some other inflammatory skin disorders and it would seem reasonable therefore to assess their activity in LS. This pilot study of 16 histologically confirmed cases of LS suggests that macrolactams have a positive pharmacological effect.
Medical subject headings
- Immunosuppressive Agents
- Lichen Sclerosus et Atrophicus
- Tacrolimus
- Vulvar Diseases